P2Y12 inhibitor monotherapy vs. DAPT soon after PCI for ACS increased a composite of death or ischemic events at 30 d but not at 1 y

Key Result

P2Y12 inhibitor monotherapy compared to DAPT soon after PCI for ACS increased the composite risk of death or ischemic events at 30 days, but not at 1 year.

Key Points

• To investigate the effects of P2Y12 inhibitor monotherapy compared to dual antiplatelet therapy (DAPT) post-percutaneous coronary intervention (PCI) in patients with acute coronary syndrome (ACS).
• Randomized trial comparing P2Y12 inhibitor monotherapy to DAPT soon after PCI.
• Evaluated composite outcomes of death or ischemic events at 30 days and 1 year.
• Increased composite of death or ischemic events at 30 days with monotherapy compared to DAPT.
• No significant difference in events between groups at 1 year.